1. A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study. Issue 6 (16th October 2020) Authors: Unseld, Matthias; Belic, Jelena; Pierer, Kerstin; Zhou, Qing; Moser, Tina; Bauer, Raimund; Piringer, Gudrun; Gerger, Armin; Siebenhüner, Alexander; Speicher, Michael; Heitzer, Ellen; Prager, Gerald W. Journal: International journal of cancer Issue: Volume 148:Issue 6(2021) Page Start: 1452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study. Issue 6 (16th October 2020) Authors: Unseld, Matthias; Belic, Jelena; Pierer, Kerstin; Zhou, Qing; Moser, Tina; Bauer, Raimund; Piringer, Gudrun; Gerger, Armin; Siebenhüner, Alexander; Speicher, Michael; Heitzer, Ellen; Prager, Gerald W. Journal: International journal of cancer Issue: Volume 148:Issue 6(2021) Page Start: 1452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The potential of liquid biopsies for the early detection of cancer. Issue 1 (December 2017) Authors: Heitzer, Ellen; Perakis, Samantha; Geigl, Jochen; Speicher, Michael Journal: Npj precision oncology Issue: Volume 1:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗